172 related articles for article (PubMed ID: 27911866)
1. DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.
Fleischer T; Klajic J; Aure MR; Louhimo R; Pladsen AV; Ottestad L; Touleimat N; Laakso M; Halvorsen AR; Grenaker Alnæs GI; Riis ML; Helland Å; Hautaniemi S; Lønning PE; Naume B; Børresen-Dale AL; Tost J; Kristensen VN
Oncotarget; 2017 Jan; 8(1):1074-1082. PubMed ID: 27911866
[TBL] [Abstract][Full Text] [Related]
2. Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
Xiao B; Chen L; Ke Y; Hang J; Cao L; Zhang R; Zhang W; Liao Y; Gao Y; Chen J; Li L; Hao W; Sun Z; Li L
BMC Cancer; 2018 Apr; 18(1):405. PubMed ID: 29642861
[TBL] [Abstract][Full Text] [Related]
3. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
4. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.
Győrffy B; Bottai G; Fleischer T; Munkácsy G; Budczies J; Paladini L; Børresen-Dale AL; Kristensen VN; Santarpia L
Int J Cancer; 2016 Jan; 138(1):87-97. PubMed ID: 26174627
[TBL] [Abstract][Full Text] [Related]
5. Gene expression and DNA methylation analyses suggest that immune process-related ADCY6 is a prognostic factor of luminal-like breast cancer.
Li W; Sang M; Hao X; Jia L; Wang Y; Shan B
J Cell Biochem; 2020 Jul; 121(7):3537-3546. PubMed ID: 31886586
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.
Zhang L; Yan DL; Yang F; Wang DD; Chen X; Wu JZ; Tang JH; Xia WJ
Oncotarget; 2017 Jul; 8(28):45496-45505. PubMed ID: 28525377
[TBL] [Abstract][Full Text] [Related]
7. DNA Methylation Based Molecular Subtypes Predict Prognosis in Breast Cancer Patients.
Wu ZH; Tang Y; Zhou Y
Cancer Control; 2021; 28():1073274820988519. PubMed ID: 33504182
[TBL] [Abstract][Full Text] [Related]
8. A novel epigenetic signature for overall survival prediction in patients with breast cancer.
Bao X; Anastasov N; Wang Y; Rosemann M
J Transl Med; 2019 Nov; 17(1):380. PubMed ID: 31747912
[TBL] [Abstract][Full Text] [Related]
9. A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.
Sun J; Chen X; Wang Z; Guo M; Shi H; Wang X; Cheng L; Zhou M
Sci Rep; 2015 Nov; 5():16553. PubMed ID: 26549855
[TBL] [Abstract][Full Text] [Related]
10. A seven-gene CpG-island methylation panel predicts breast cancer progression.
Li Y; Melnikov AA; Levenson V; Guerra E; Simeone P; Alberti S; Deng Y
BMC Cancer; 2015 May; 15():417. PubMed ID: 25986046
[TBL] [Abstract][Full Text] [Related]
11. Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer.
Zhang Y; Yu C
BMC Cancer; 2020 Jun; 20(1):575. PubMed ID: 32560641
[TBL] [Abstract][Full Text] [Related]
12. Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
Wahabi K; Perwez A; Kamarudheen S; Bhat ZI; Mehta A; Rizvi MMA
BMC Cancer; 2019 Aug; 19(1):820. PubMed ID: 31429726
[TBL] [Abstract][Full Text] [Related]
13. Identifying prognostic subgroups of luminal-A breast cancer using deep autoencoders and gene expressions.
Wang S; Lee D
PLoS Comput Biol; 2023 May; 19(5):e1011197. PubMed ID: 37253056
[TBL] [Abstract][Full Text] [Related]
14. Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
Tishchenko I; Milioli HH; Riveros C; Moscato P
PLoS One; 2016; 11(6):e0158259. PubMed ID: 27341628
[TBL] [Abstract][Full Text] [Related]
15. Identification of Methylation Markers and Differentially Expressed Genes with Prognostic Value in Breast Cancer.
Wu J; Zhang Y; Li M
J Comput Biol; 2019 Dec; 26(12):1394-1408. PubMed ID: 31290690
[TBL] [Abstract][Full Text] [Related]
16. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.
Conway K; Edmiston SN; May R; Kuan PF; Chu H; Bryant C; Tse CK; Swift-Scanlan T; Geradts J; Troester MA; Millikan RC
Breast Cancer Res; 2014 Oct; 16(5):450. PubMed ID: 25287138
[TBL] [Abstract][Full Text] [Related]
18. A specific gene expression signature for visceral organ metastasis in breast cancer.
Savci-Heijink CD; Halfwerk H; Koster J; Horlings HM; van de Vijver MJ
BMC Cancer; 2019 Apr; 19(1):333. PubMed ID: 30961553
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients.
Figueroa JD; Yang H; Garcia-Closas M; Davis S; Meltzer P; Lissowska J; Horne HN; Sherman ME; Lee M
Breast Cancer Res Treat; 2015 Apr; 150(2):457-466. PubMed ID: 25773928
[TBL] [Abstract][Full Text] [Related]
20. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.
Perez-Janices N; Blanco-Luquin I; Torrea N; Liechtenstein T; Escors D; Cordoba A; Vicente-Garcia F; Jauregui I; De La Cruz S; Illarramendi JJ; Coca V; Berdasco M; Kochan G; Ibañez B; Lera JM; Guerrero-Setas D
Oncotarget; 2015 Sep; 6(27):23944-58. PubMed ID: 26284587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
